ArticleFrontiers in oncology2026
Patterns, causes, and clinical impact of treatment interruption on early outcomes in patients receiving radiotherapy for lung cancer: a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiation therapy is key for lung cancer, but data on unplanned interruptions remains limited. Objectives: This study investigated patterns, risk factors, and clinical impacts of radiotherapy interruptions in lung cancer patients. Methods: A retrospective study enrolled 230 lung cancer patients undergoing radiotherapy (Jan 2020-Dec 2022). After exclusion, 226 patients were analyzed and stratified into interrupted and non-interrupted groups by unplanned radiotherapy interruptions (≥1-day pause, excluding scheduled breaks). Patterns and causes of interruptions were documented in detail. Early oncological response, treatment completion, acute toxicities, progression-free survival (PFS), and overall survival (OS) were monitored at 6 months post-radiotherapy. Multivariable linear regression identified interruption risk factors, while Cox regression and Kaplan-Meier analysis with log-rank test evaluated survival. Results: A total of 226 lung cancer patients were enrolled, 79 (34.96%) of whom had at least one treatment interruption, with a median duration of 5 days and 1 episode. Most interruptions occurred in the middle third of radiotherapy (60.76%), mainly caused by treatment-related toxicities (49.37%) and patient-related factors (27.85%). Multivariable linear regression showed that performance status (PS) score 2-3, stage III-IV and tumor volume ≥50 cm³ remained significantly associated with radiotherapy interruption after adjustment for potential confounders (all P<0.05). The interrupted group had poorer compliance, lower overall response rate (ORR) and disease control rate (DCR), higher acute toxicities. Unadjusted Kaplan-Meier analysis showed worse 6-month PFS and OS in the interrupted group, and this association persisted in multivariable-adjusted Cox regression after controlling for PS score, tumor stage, tumor volume, treatment regimen, and radiotherapy modality (all P < 0.001). Conclusions: Radiotherapy interruption is common in lung cancer patients, mainly caused by toxicity. It impairs treatment efficacy and survival, requiring individualized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.